BioInvent International AB (OSTO:BINV)

kr 43.2 -0.05 (-0.12%) Market Cap: 2.84 Bil Enterprise Value: 1.80 Bil PE Ratio: 0 PB Ratio: 2.59 GF Score: 59/100

Q4 2023 BioInvent International AB Earnings Call Transcript
Feb 22, 2024

kr15.78 (+0.90%)

Earnings
Q3 2023 BioInvent International AB Earnings Call Transcript
Oct 26, 2023

kr15.18 (-1.04%)

Earnings
BioInvent International AB at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Full Year 2022 BioInvent International AB Earnings Call Transcript
Feb 22, 2023

kr30.2 (+1.34%)

Earnings
BioInvent International AB R&D Day Transcript
Dec 08, 2022
BioInvent International AB at Biostock Life Science Fall Summit Transcript
Nov 29, 2022
Q3 2022 BioInvent International AB Earnings Call Transcript
Oct 27, 2022

kr40.3 (-3.24%)

Earnings
Q4 2021 BioInvent International AB Earnings Call Transcript
Feb 23, 2022

kr35.46 (+3.68%)

Earnings
BioInvent International AB at Redeye Fight Cancer Seminar (Virtual) Transcript
Jan 20, 2022
Q3 2021 BioInvent International AB Earnings Call Transcript
Oct 28, 2021

kr36.62 (+1.16%)

Earnings
BioInvent International AB CEO Presentation - Pre Recorded Transcript
Apr 28, 2021
Q4 2020 BioInvent International AB Earnings Call Transcript
Feb 23, 2021

kr51 (+4.77%)

Earnings
Q2 2020 BioInvent International AB Earnings Call Transcript
Aug 27, 2020

kr40 (+0.38%)

Earnings
Q4 2019 BioInvent International AB Earnings Call Transcript
Feb 27, 2020

kr32.42 (-3.79%)

Earnings

BioInvent International AB at Biostock Life Science Fall Summit Transcript

Nov 29, 2022 - Nov 30, 2022 / NTS GMT

Release Date Price: kr35.55 (-0.42%)

Transcript

Martin Welschof

BioInvent International AB - CEO

Happy to be here. And we'll try to give you a very condensed story of BioInvent, where we are at the moment, and the current status. Obviously, we are listed in Stockholm, as everybody know. So this is our forward-looking statement.

And then I would like to start with a quick snapshot of the company. So what we're doing at BioInvent, and obviously BioInvent is an expert in antibody discovery and development. But we have refocused a little bit in that sense that we are currently leveraging, as it says on this slide here, cancer biology, knowledge, immunology, and then antibody expertise.

And we're a little bit different to a lot of companies, so we are really pushing out with a broad portfolio. As you can see, we have currently five clinical projects running. And by next year, actually, we'll start our program number six. And this is possible since we are quite integrated company. So we do discovery of targets and antibodies based on a functional screening approach, which I will explain to you quickly on the next slide. We have

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.